Carolina Rudah/iStock via Getty Images European Union antitrust officials are asking rival pharmaceuticals firms for their input on Novo Holdings planned $16.5 billion purchase of Catalent ( NYSE: CTLT ). The questionnaire from the European Commission seeks feedback on vertical links in the contract development and manufacturing industry, according.
